TABLE 2.
Agreement of the MB method and the VITEK 2 system for 97 blood culture-positive isolates
| Antibiotic | No. (%) of strains with:
|
||||
|---|---|---|---|---|---|
| MIC agreementa | Category agreementb | Minor discrep- ancyc | Major discrep- ancyd | Very major discrep- ancye | |
| Amikacin | 95 (97.9%) | 2 | 0 | 0 | 0 |
| Cefepime | 90 (92.8%) | 3 | 3 | 0 | 1 |
| Ceftazidime | 96 (99.0%) | 1 | 0 | 0 | 0 |
| Ciprofloxacin | 88 (90.7%) | 8 | 0 | 1 | 0 |
| Gentamicin | 96 (99.0%) | 1 | 0 | 0 | 0 |
| Imipenem | 97 (100.0%) | 0 | 0 | 0 | 0 |
| Meropenem | 96 (99.0%) | 1 | 0 | 0 | 0 |
| Netilmicin | 91 (93.8%) | 3 | 2 | 1 | 0 |
| Piperacillin | 86 (88.7%) | 2 | 8 | 1 | 0 |
| Piperacillin-tazo- bactam | 87 (89.7%) | 3 | 5 | 1 | 1 |
| Tobramycin | 94 (96.9%) | 1 | 2 | 0 | 0 |
a
±1 twofold dilution.
b
MICs differed by >1 twofold dilution.
c
Reported as susceptible or resistant with VITEK 2 system and intermediate by the reference test or intermediate with the VITEK 2 system and susceptible or resistant by the reference test.
d
Reported as resistant with the VITEK 2 system and susceptible by the reference test.
e
Reported as susceptible with the VITEK 2 system and resistant by the reference test.